Inactive Instrument

Grindeks

GRD1R

LV0000100659

Joint Stock Company "Grindeks" Provides Turnover Guidance for the Year 2012

February 25, 2013 at 06:21 am EST

Joint Stock Company "Grindeks" provided turnover guidance for the year 2012. The turnover of the Group in 2011 was LVL 69.6 million. Indicator of the turnover in 2012 will reach the increase above 10%, compared to the previous year.

Latest news about Grindeks

Grindeks Opens New Subsidiaries Worldwide	Apr. 03	CI
JSC Grindeks Appoints Andrejs Liberts as the Member of the Board	21-02-24	CI
SIA Liplat Holding completed the acquisition of additional 2.6% stake in Akciju sabiedriba Grindeks for €3.4 million.	21-01-21	CI
SIA Liplat Holding made an offer to acquire the remaining 5.84% stake in Akciju sabiedriba Grindeks for €7.6 million.	20-12-21	CI
Akciju Sabiedriba Grindeks Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-26	CI
Akciju Sabiedriba Grindeks Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-27	CI
Grindeks Completes Phase 1 Clinical Study of its New Investigational Medicinal Product Methyl-GBB	20-03-05	CI
As Grindeks Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-28	CI
JSC Grindeks Announces Appointment of Juris Hmelnickis as the Chairman of the Board	20-02-04	CI
JSC Grindeks Announces Resignation of Juris Bundulis as Chairman of the Board	20-01-22	CI
JSC Grindeks Receives A Certificate of Saudi Food and Drug Authority	19-12-19	CI
As Grindeks Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-28	CI
As Grindeks Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-29	CI
Dashdirect Limited, Kirovs Lipmans, Anna Lipmane and Filips Lipmans completed the acquisition of 20.17% stake AS Grindeks for €24.3 million.	19-06-27	CI
AS Grindeks Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019	19-05-30	CI
Dashdirect Limited, Kirovs Lipmans, Anna Lipmane and Filips Lipmans have bid to acquire remaining 27.36% stake in AS Grindeks for €33 million.	19-05-23	CI
Dashdirect Limited, Kirovs Lipmans, Anna Lipmane and Filips Lipmans acquired an additional 22.66% stake in AS Grindeks from AmberStone Group, AS.	19-05-22	CI
Grindeks Announces Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2018	19-04-30	CI
Grindeks Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2018; Provides Group Earnings Guidance for the Full Year of Fiscal 2019	19-02-28	CI
AS Grindeks Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-29	CI
JSC Grindeks Reports Unaudited Consolidated Earnings Results for the First Half Ended June 30, 2018	18-08-31	CI
JSC Grindeks and Latvian Institute of Organic Synthesis Sign New Agreement on Drug Research and Development	18-08-22	CI
JSC Grindeks Concludes Land Purchase Agreement for Innovation Centre Development	18-08-08	CI
Joint Stock Company "Grindeks" completed the acquisition of HBM Pharma sro from Dashdirect Limited for €18.2 million.	18-06-20	CI
AS Grindeks Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018; Provides Group Earnings Guidance for the Full Year of Fiscal 2018	18-05-31	CI

Chart Grindeks

Duration

Period

More charts

Company Profile

Grindeks is the Baltic leader pharmaceutical group. Net sales break down by activity as follows: - research, development and manufacturing of pharmaceuticals (94.9%): medicines for the treatment of cardiovascular diseases, cancers and central nervous system disorders, analgesic products, treatments of cough and flu, etc.; - production of pharmaceutical active ingredients (5.1%). Net sales break down geographically as follows: Latvia (6.6%), Russia (59.6%), Lithuania (4%), Estonia (1.7%) and other (28.1%).

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+13.53%	41.95B
OTSUKA HOLDINGS CO., LTD.	+22.20%	22.53B
SANDOZ GROUP AG	+15.00%	14.91B
CIPLA LIMITED	+17.35%	14.11B
ZYDUS LIFESCIENCES LIMITED	+45.62%	12.5B
ONO PHARMACEUTICAL CO., LTD.	-9.44%	6.75B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.55%	5.6B

Generic Pharmaceuticals